Merus saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 77 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating as they launch their biggest runs.
While it's not currently an ideal time to invest, see if the stock is able to form a consolidation and break out.
The company posted 0% EPS growth in the latest quarterly report. Sales gains came in at 236%.
Merus holds the No. 140 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
